Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Raised by Focus Partners Wealth

Focus Partners Wealth boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 191.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,319 shares of the company's stock after purchasing an additional 1,523 shares during the period. Focus Partners Wealth's holdings in Medpace were worth $775,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. R Squared Ltd acquired a new stake in Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace during the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp raised its stake in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC raised its stake in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. raised its stake in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Trading Up 0.6%

MEDP traded up $1.86 during trading hours on Friday, hitting $294.89. The company's stock had a trading volume of 266,217 shares, compared to its average volume of 354,458. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77. The firm has a market capitalization of $8.48 billion, a PE ratio of 23.35, a PEG ratio of 3.81 and a beta of 1.55. The company has a 50-day simple moving average of $301.83 and a 200 day simple moving average of $326.78.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The firm had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same period last year, the firm earned $3.20 EPS. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Leerink Partners assumed coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Robert W. Baird cut their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partnrs upgraded Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Truist Financial dropped their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $349.30.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.30% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.